{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:21:53Z","timestamp":1786119713695,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      Patients with metastatic castration-resistant prostate cancer (mCRPC) often undergo multiple treatments, making accurate response assessment vital. The conventional imaging-based PCWG3 criteria, incorporating the RECIST-1.1, have been the gold standard so far. Although\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11-PET\/CT has shown an incremental role in staging of prostate cancer, its utility in response evaluation lacks prospective validation. Here, we prospectively evaluate different\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11-PET\/CT\u2013based response evaluation criteria, including RECIP-1.0, PPP, and aPERCIST, and compare these with the PCWG3 criteria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      mCRPC patients, initiating treatment with taxanes, androgen-receptor pathway inhibitors (ARPIs), or\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617, underwent\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11-PET\/CT and conventional imaging (CECT and bone scintigraphy) at baseline, and every 12 weeks after treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty-four mCRPC patients were included (median age: 68.5\u00a0y, median PSA: 61.9\u00a0ng\/mL). Nonprogression rates at 12 weeks according to PCWG3, aPERCIST, PPP, and RECIP-1.0 were 23.5%, 8.8%, 17.6%, and 23.5%, respectively. The highest inter-reader agreement was observed with RECIP-1.0 (\u03ba=0.84). The median OS was 16.5 months with nonprogression according to PCWG3 being associated with significantly better OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.02), and no significant associations were observed with the rest of the criteria. In surrogacy analysis of rPFS for OS in the overall cohort, the highest C-index was observed for PCWG3-rPFS (C=0.72), followed by RECIP-rPFS (C=0.71). In subgroup analyses, RECIP-rPFS had the highest C-index for non-ARPI patients (C=0.76), and PCWG3-rPFS for the ARPI patients (C=0.75).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PCWG3 remains the most effective response criterion overall and for ARPI-treated patients, while RECIP-1.0 showed better prognostic value for non-ARPI patients. Larger studies are needed to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006147","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T19:00:28Z","timestamp":1767812428000},"page":"e100-e107","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["68Ga-PSMA-11 PET\/CT Versus Conventional Imaging for Response Evaluation in Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4819-5547","authenticated-orcid":false,"given":"Komal","family":"Preet","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7228-0361","authenticated-orcid":false,"given":"Ashwani","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-6644","authenticated-orcid":false,"given":"Swayamjeet","family":"Satapathy","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab"},{"name":"Department of Nuclear Medicine, MPMMCC & HBCH, Tata Memorial Centre, Varanasi, Uttar Pradesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9972-6682","authenticated-orcid":false,"given":"Shikha","family":"Goyal","sequence":"additional","affiliation":[{"name":"Radiotherapy and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-3113","authenticated-orcid":false,"given":"Piyush","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1369-7479","authenticated-orcid":false,"given":"Ravimohan S.","family":"Mavuduru","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4142-1592","authenticated-orcid":false,"given":"Gaurav","family":"Prakash","sequence":"additional","affiliation":[{"name":"Clinical Haematology and Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5984-379X","authenticated-orcid":false,"given":"Priyavrat","family":"Purohit","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3578-0377","authenticated-orcid":false,"given":"Pritika","family":"Dhiman","sequence":"additional","affiliation":[{"name":"Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-5783","authenticated-orcid":false,"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"R1-20260107","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"R2-20260107","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R3-20260107","doi-asserted-by":"crossref","first-page":"1758835920987654","DOI":"10.1177\/1758835920987654","article-title":"Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging","volume":"13","author":"Conteduca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"R4-20260107","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.3390\/cancers14184470","article-title":"Bone scintigraphy versus PSMA-targeted PET\/CT or PET\/MRI in prostate cancer: lessons learned from recent systematic reviews and meta-analyses","volume":"14","author":"Dondi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R5-20260107","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"key":"R6-20260107","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R7-20260107","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.3390\/cancers16244263","article-title":"Current clinical applications of PSMA-PET for prostate cancer diagnosis, staging, and treatment","volume":"16","author":"von Stauffenberg","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R8-20260107","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"R9-20260107","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET Response Criteria in Solid Tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology"},{"key":"R10-20260107","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2967\/jnumed.119.233817","article-title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria","volume":"61","author":"Fanti","year":"2020","journal-title":"J Nucl Med"},{"key":"R11-20260107","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"R12-20260107","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.118.223099","article-title":"Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade","volume":"60","author":"Emmett","year":"2019","journal-title":"J Nucl Med"},{"key":"R13-20260107","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/pros.23522","article-title":"Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells","volume":"78","author":"Kranzb\u00fchler","year":"2018","journal-title":"Prostate"},{"key":"R14-20260107","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","article-title":"SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T","volume":"50","author":"Hartrampf","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20260107","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11307-024-01900-6","article-title":"Pre-treatment 68Ga-PSMA-11 PET\/CT prognostic value in predicting response to 177Lu-PSMA-I&T therapy and patient survival","volume":"26","author":"Eisazadeh","year":"2024","journal-title":"Mol Imaging Biol"},{"key":"R16-20260107","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bju.15151","article-title":"Use of prostate-specific membrane antigen positron-emission tomography\/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer","volume":"126","author":"Anton","year":"2020","journal-title":"BJU Int"},{"key":"R17-20260107","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R18-20260107","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.7150\/thno.39838","article-title":"Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria","volume":"10","author":"Velez","year":"2020","journal-title":"Theranostics"},{"issue":"Suppl 1(suppl 1","key":"R19-20260107","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"R20-20260107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13550-021-00754-1","article-title":"Quantitation of cancer treatment response by 2-[18F]FDG PET\/CT: multi-center assessment of measurement variability using AUTO-PERCISTT","volume":"11","author":"OJH","year":"2021","journal-title":"M EJNMMI Res"},{"key":"R21-20260107","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07351-7","article-title":"Novel framework for response evaluation criteria in grade 1\/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial","author":"Satapathy","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R22-20260107","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13550-023-01044-8","article-title":"Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer","volume":"13","author":"Wang","year":"2023","journal-title":"EJNMMI Res"},{"key":"R23-20260107","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat Rev Urol"},{"key":"R24-20260107","doi-asserted-by":"crossref","first-page":"e162907","DOI":"10.1172\/jci.insight.162907","article-title":"Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer","volume":"8","author":"Sayar","year":"2023","journal-title":"JCI Insight"},{"key":"R25-20260107","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.eururo.2019.07.030","article-title":"Tumour heterogeneity and resistance to therapy in prostate cancer: a fundamental limitation of prostate-specific membrane antigen theranostics or a key strength?","volume":"76","author":"Hofman","year":"2019","journal-title":"Eur Urol"},{"key":"R26-20260107","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2967\/jnumed.120.260836","article-title":"Assessing response to [177Lu]PSMA radioligand therapy using modified PSMA PET progression criteria","volume":"62","author":"Michalski","year":"2021","journal-title":"J Nucl Med"},{"key":"R27-20260107","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:00:19Z","timestamp":1786042819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006147"}},"subtitle":["A Single-center Prospective Study"],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006147","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"2025-08-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}